Evidence map›Paper›PMID 41675168›Full record

ArticleiMetaOmics2025

Interactions between

Fujian Qin, Mengdi Zhang, Qingling Yang, Lei Wu, Tianxiao Mao, Xingchen Zhou, Jing Li, Maode Lai

Abstract read
In one paragraph

Article in iMetaOmics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Frontiers in microbiology · 2026
    Article
  5. Gut Commensal Antibiotic-ResistantResearch (Washington, D.C.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fujian QinState Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy China Pharmaceutical University Nanjing China.ORCID 0000-0002-4917-9342
Mengdi ZhangState Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy China Pharmaceutical University Nanjing China.
Qingling YangState Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy China Pharmaceutical University Nanjing China.
Lei WuDepartment of Laboratory Medicine The First Affiliated Hospital of Nanjing Medical University Nanjing China.
Tianxiao MaoDepartment of Pharmacy Zhongshan Hospital Fudan University Shanghai China.
Xingchen ZhouDivision of (Bio) Pharmaceutics Institute of Zhejiang University-Quzhou Quzhou China.
Jing LiSchool of Life Science and Technology China Pharmaceutical University Nanjing China.ORCID 0000-0001-9972-7397
Maode LaiState Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy China Pharmaceutical University Nanjing China.ORCID 0000-0001-6830-9774

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic disorder linked to an increased risk of colorectal cancer (CRC) and is characterized by significant dysbiosis in the gut microbiota. The commensal bacterium

Indexed as

bile acidcolorectal cancerfiber free dietinflammatory bowel diseaseParabacteroides goldsteinii

Identifiers

PMID41675168
PMCPMC12806366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.